AstraZeneca
industry leading outlook to and beyond ambition to launch at least by mid to long term ambition strong underlying revenue and profitability growth total revenue excluding covid medicines to increase by low double digit total revenue including covid to increase by low to mid single digit core to increase by high single digit to low double digit transitioning covid medicines continued existing medicines growth managing franchise transitions combinations late stage pipeline delivery new in new phase trials including potential blockbusters mid stage pipeline delivery all tas new technologies accelerating science led innovation | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
8 of 45
Related slides by other companies
OpenText
Investor Presentation
February 2023
track record of total revenue growth double digit | OpenText
Yatsen
Results
August 2023
operating expenses it | Yatsen
Alkermes
Results
July 2023
financial results summary | Alkermes
LiveVox
Results
May 2023
by the numbers increase outen revenue | LiveVox
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io